GlaxoSmithKline PLC (NYSE:GSK) : Average target price received by GlaxoSmithKline PLC (NYSE:GSK) is $48.5 with an expected standard deviation of $0.71. The most aggressive target on the stock is $49, whereas the most downbeat target is $48. 2 financial analysts are currently covering the stock.
Shares of GlaxoSmithKline plc rose by 1.83% in the last five trading days and 2.8% for the last 4 weeks. GlaxoSmithKline plc is up 8.84% in the last 3-month period. Year-to-Date the stock performance stands at 12.29%.
GlaxoSmithKline PLC (NYSE:GSK) : The consensus on GlaxoSmithKline PLC (NYSE:GSK) based on 5 analyst recommendation on the company stock is 2.6, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
GlaxoSmithKline PLC (NYSE:GSK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $42.52 and $42.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $43.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $43.34, notching a gain of 2.07% for the day. The total traded volume was 4,657,715 . The stock had closed at $42.46 on the previous day.
GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.